CHILDREN'S CANCER STUDY GROUP

费城儿童医院为这项研究做出了贡献 儿童癌症研究小组最近20年的科学 关于患者进入研究，科学领导在 委员会和战略小组，以及发起和执行 先导研究的结果。具体贡献如下： 1)铁蛋白作为神经母细胞瘤生物标志物的研究进展 神经母细胞瘤的活动性及组织病理学分类 延续了埃文斯和丹吉奥在舞台上的早期工作 2)发展一种多学科的神经-- 肿瘤学课程包括神经外科、放射学、放射学 治疗、神经学和儿科肿瘤学，已经发展 成功的脑肿瘤临床试验，但没有一个是 在集团中可用。这些已经并将被合并到 随机分组试验；3)启动实施方法 利用随机数字拨号技术进行流行病学研究 并负责视网膜母细胞瘤的小组研究和 通过NCI资助的赠款获得脑瘤；4提供领导广告 开展癌症治疗远期效应研究方面的专门知识； 以及5)进行白血病、霍奇金氏病、 淋巴瘤、横纹肌肉瘤、肾母细胞瘤和脑肿瘤 作为该集团的早期飞行员。参与调查的调查人员 这项工作将继续为以下工作提供高质量的数据 每年有超过1,000名患者参加CCG研究 在学习中被跟踪；预计这个数字将 由于脑瘤、霍奇金氏病和 二线白血病治疗药物现已问世。大约70 新的脑肿瘤患者和15名霍奇金氏病患者和 每年都会在这里看到所有复发的人；至少会有50人进入 关于以前没有的研究。有20名调查人员 在这个拥有96个学习委员会职位的机构里， 战略小组或科学委员会，其中19个在 担任领导职务。我们将继续招收所有符合条件的人 患者，并符合小组关于研究的要求 参与，除了在具体的 上面提到的领域。

The children's Hospital of Philadelphia has contributed to the science of the Children's Cancer Study Group in the last 20 years with regard to patient entry on study, scientific leadership in committees and strategy groups, and the initiation and performance of pilot studies. Specific contributions have been the following: 1) Development of ferritin as a biologic marker of neuroblastoma activity and of a histopathologic classification of neuroblastoma following on the earlier work of Evans and D'Angio in the staging of that disease; 2) Development of a multidisciplinary nero- oncology program consisting of neurosurgery, radiology, radiation therapy, neurology and pediatric oncology, which has developed successful clinical trials for brain tumors when none were available in the Group. These have and will be incorporated into randomized Group trials; 3) Initiation of a method of performing edpidemiologic studies utilizing the random-digit dialing technique and assuming responsibility for Group studies of retinoblastoma and brain tumors through NCI funded grants; 4 Providing leadership ad expertise in developing studies of late effects of cncer therapy; and 5) Performing studies for leukemia, Hodgkin's disease, lymphomas, rhabdomyosarcoma, Wilms' tumor, and brain tumors serving as early pilots for the Group. The investigators participating in this endeavor will continue to provide data of high quality for patients entered on CCG studies annually and more than 1,000 are being followed on study; it is expectd that this number will increase in the future since brain tumor, hodgkin's disease and second-line leukemia sxtudies are now available. Approximately 70 new brain tumor patients and 15 each with Hodgkin's disease and relapsed ALL are seen annually here; at least 50 will be entered on studies not previously available. There are 20 investigators in this institution holding 96 positions on study committees, strategy groups, or scientific committees, 19 of them being in positions of leadership. We will continue to enroll all eligible patients and to coform to group requirements with regard to study participation, in addition to providing leadership in the specific areas noted above.